Intravitreal injections in clinical practice: results of a survey of eye surgeons in the Ural federal district

Cover Page

Cite item

Full Text

Abstract

Introduction. Intravitreal i njections ( IVI) are widespread in modern ophthalmology as a method of drug delivery in various posterior segment pathologies. Despite the accumulated experience, some aspects of the procedure remain debatable. In addition, in the literature there are no data on the practical aspects of IVI performance in real clinical conditions in Russia. This article presents the results of an anonymous survey of 74 ophthalmologists of the Ural Federal District of the Russian Federation, conducted in 2018 using an original questionnaire, which included 20 questions. It was revealed that respondents generally share the traditional for Russia approach to IVI as to major ophthalmic surgery. The survey revealed a lack of common approaches and incomplete adherence to modern guidelines in certain aspects of the procedure, and therefore correcting measures were proposed.

About the authors

Sergey A. Korotkikh

Ural State Medical University

Email: secretar@mcprof.ru
SPIN-code: 6440-7706

MD, PhD, Professor, Head of the Department of Ophthalmology

Russian Federation, Yekaterinburg

Evgeniy V. Bobykin

Ural State Medical University

Author for correspondence.
Email: oculist.ev@gmail.com
ORCID iD: 0000-0001-5752-8883
SPIN-code: 2705-1425
Scopus Author ID: 26430475300

MD, PhD, Professor Associate, Assistant Professor of the Department of Ophthalmology

Russian Federation, Yekaterinburg

Valerij F. Ekgardt

South-Ural State Medical University

Email: valeriy.ekgardt@mail.ru

MD, PhD, Professor, Head of the Eye Diseases Department

Russian Federation, Chelyabinsk

Tatiana N. Malishevskaya

Regional Ophthalmologic Clinic

Email: malishevskoff@yandex.ru

MD, PhD, Head of Department of Medical Care Organization

Russian Federation, Tyumen

Irina A. Kubareva

Kurgan Regional Hospital for War Veterans

Email: irina.kubareva2015@yandex.ru

MD, PhD, Ophthalmologist

Russian Federation, Kurgan

Tatiana G. Akulevich

District Clinical Hospital

Email: AkulevichTG@okbhmao.ru

Ophthalmologist

Russian Federation, Khanty-Mansiysk

Olga V. Morozova

Ural State Medical University

Email: s.rafias@gmail.com

Ophthalmologist, Applicant of the Department of Ophthalmology

Russian Federation, Yekaterinburg

References

  1. Ohm J. Über die Behandlung der Netzhautablösung durch operative Entleerung der subretinalen Flüssigkeit und Einspritzung von Luft in den Glaskörper. Albrecht von Graefe’s Archiv für Ophthalmologie. 1911;79(3):442-450. https://doi.org/10.1007/bf01977971.
  2. Бойко Э.В., Сосновский С.В., Березин Р.Д., и др. Интравитреальные инъекции: теория и практика // Офтальмологические ведомости. – 2010. – Т. 3. – № 2. – С. 28–35. [Boyko EV, Sosnovskiy SV, Berezin RD, et al. Intravitreal injections: theory and practices. Ophthalmology journal. 2010;3(2):28-35. (In Russ.)]
  3. Ramulu PY, Do DV, Corcoran KJ, et al. Use of retinal procedures in medicare beneficiaries from 1997 to 2007. Arch Ophthalmol. 2010;128(10):1335-40. https://doi.org/10.1001/archophthalmol.2010.224.
  4. Peyman GA, Lad EM, Moshfeghi DM. Intravitreal injection of therapeutic agents. Retina. 2009;29(7):875-912. https://doi.org/10.1097/IAE.0b013e3181a94f01.
  5. Williams GA. IVT injections: health policy implications. Review of ophthalmology [Internet]. 2014 [cited 2019 Mar 28]. Available from: https://www.reviewofophthalmology.com/article/ivt-injections-health-policy-implications.
  6. Charles S. The Future of Surgical Retina in the Era of Medical Retina. Retin Physician. 2017;14:23-25.
  7. Lee SS, Hughes PM, Robinson MR. Recent advances in drug delivery systems for treating ocular complications of systemic diseases. Curr Opin Ophthalmol. 2009;20(6):511-519. https://doi.org/10.1097/ICU.0b013e328330ccb9.
  8. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431. https://doi.org/10.1056/NEJMoa054481.
  9. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615-625. https://doi.org/10.1016/j.ophtha.2011.01.031.
  10. Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology. 2012;119(4):802-809. https://doi.org/10.1016/j.ophtha.2011.12.005.
  11. Holz FG, Bandello F, Gillies M, et al. Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme. Br J Ophthalmol. 2013;97(9):1161-1167. https://doi.org/10.1136/bjophthalmol-2013-303232.
  12. Holz FG, Tadayoni R, Beatty S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99(2):220-226. https://doi.org/10.1136/bjophthalmol-2014-305327.
  13. Охоцимская Т.Д., Зайцева О.В. Афлиберцепт в лечении заболеваний сетчатки. Обзор клинических исследований // Российский офтальмологический журнал. – 2017. – Т. 10. – № 2. – С. 103–111. [Okhotsimskaya TD, Zaitseva OV. Aflibercept for the therapy of retinal diseases. A review of clinical studies. Rossiiskii oftal’mologicheskii zhurnal. 2017;10(2):103-111. (In Russ.)]. https://doi.org/10.21516/2072-0076-2017-10-2-103-111
  14. Bobykin E, Morozova O, Buslaev R. The Duration of Anti-VEGF Therapy of Macular Diseases in Russian Patients: Real Clinical Practice. Ophthalmic Res. 2018;60(Suppl 1):17.
  15. Aiello LP, Brucker AJ, Chang S, et al. Evolving Guidelines for Intravitreous Injections. Retina. 2004;24(Supplement): S 3-S 19. https://doi.org/10.1097/00006982-200410001-00002.
  16. Grzybowski A, Told R, Sacu S, et al. 2018 Update on Intravitreal Injections: Euretina Expert Consensus Recommendations. Ophthalmologica. 2018;239(4):181-193. https://doi.org/10.1159/000486145.
  17. Villegas VM, Schwartz SG, Grzybowski A, et al. Endophthalmitis Prophylaxis: Different Practices from Around the World. In: Endophthalmitis. Ed. by T. Das. Singapore: Springer; 2018. https://doi.org/10.1007/978-981-10-5260-6_29.
  18. Green-Simms AE, Ekdawi NS, Bakri SJ. Survey of intravitreal injection techniques among retinal specialists in the United States. Am J Ophthalmol. 2011;151(2):329-332. https://doi.org/10.1016/j.ajo.2010.08.039.
  19. Huang K, Sultan MB, Zhou D, et al. Practice patterns of ophthalmologists administering intravitreal injections in Europe: a longitudinal survey. Clin Ophthalmol. 2016;10:2485-2488. https://doi.org/10.2147/OPTH.S 117801.
  20. Turnbull AMJ, Trikha S, Khandhadia S, et al. The National Intravitreal Injection Survey: a look at current practice. International Journal of Ophthalmic Practice. 2011;2(3):117-122. https://doi.org/10.12968/ijop.2011.2.3.117.
  21. Segal O, Segal-Trivitz Y, Nemet AY, et al. Survey of intravitreal injection techniques among retina specialists in Israel. Clin Ophthalmol. 2016;10:1111-1116. https://doi.org/10.2147/OPTH.S 96452.
  22. Xing L, Dorrepaal SJ, Gale J. Survey of intravitreal injection techniques and treatment protocols among retina specialists in Canada. Can J Ophthalmol. 2014;49(3):261-266. https://doi.org/10.1016/j.jcjo.2014.03.009.
  23. Shiroma HF, Farah ME, Takahashi WY, et al. Survey: technique of performing intravitreal injection among members of the Brazilian Retina and Vitreous Society (SBRV). Arq Bras Oftalmol. 2015;78(1):32-35. https://doi.org/10.5935/0004-2749.20150009.
  24. Бойко Э.В., Сосновский С.В., Березин Р.Д., и др. Антиангиогенная терапия в офтальмологии. — СПб.: ВМедА им. С.М. Кирова, 2013. [Boyko EV, Sosnovskiy SV, Berezin RD, et al. Antiangiogennaya terapiya v oftal’mologii. Saint Petersbueg: VMedA im. S.M. Kirova; 2013. (In Russ.)]
  25. Grzybowski A, Brona P, Kim SJ. Microbial flora and resistance in ophthalmology: a review. Graefes Arch Clin Exp Ophthalmol. 2017;255(5):851-862. https://doi.org/10.1007/s00417-017-3608-y.
  26. Bremond-Gignac D, Chiambaretta F, Milazzo S. A European perspective on topical ophthalmic antibiotics: current and evolving options. Ophthalmol Eye Dis. 2011;3:29-43. https://doi.org/10.4137/OED.S 4866.
  27. Астахов Ю.С., Белехова С.Г., Литвинова Е.А. Инфекционный и стерильный эндофтальмит после интравитреальных инъекций: дифференциальная диагностика, профилактика, лечение // Офтальмологические ведомости. – 2017. – Т. 10. – № 1. – С. 62–69. [Astakhov YS, Belekhova SG, Litvinova EA. Infectious and sterile endophthalmitis after intravitreal injections: differential diagnosis, prevention, treatment. Ophthalmology journal. 2017;10(1):62-69. (In Russ.)]. https://doi.org/10.17816/OV10162-69.
  28. Bande MF, Mansilla R, Pata MP, et al. Intravitreal injections of anti-VEGF agents and antibiotic prophylaxis for endophthalmitis: A systematic review and meta-analysis. Sci Rep. 2017;7(1):18088. https://doi.org/10.1038/s41598-017-18412-9.
  29. Иошин И.Э. Безопасность интравитреальных инъекций // Офтальмохирургия. – 2017. – № 3. – С. 71–79. [Ioshin IE. Safety of intravitreal injections. Ophthalmosurgery. 2017;(3):71-79. (In Russ.)] https://doi.org/10.25276/0235-4160-2017-3-71-79.
  30. Avery RL, Bakri SJ, Blumenkranz MS, et al. Intravitreal injection technique and monitoring: updated guidelines of an expert panel. Retina. 2014;34 Suppl 12: S 1-S 18. https://doi.org/10.1097/IAE.0000000000000399.
  31. Lai TY, Liu S, Das S, Lam DS. Intravitreal Injection – Technique and Safety. Asia Pac J Ophthalmol (Phila). 2015;4(6):321-328. https://doi.org/10.1097/APO.0000000000000146.
  32. Поляк М.С., Околов И.Н., Пирогов Ю.И. Антибиотики в офтальмологии. — СПб.: Нестор-История, 2015. [Polyak MS, Okolov IN, Pirogov YI. Antibiotiki v oftal’mologii. Saint Petersburg: Nestor-Istoriya; 2015. (In Russ.)]
  33. Behndig A, Cochener B, Guell JL, et al. Endophthalmitis prophylaxis in cataract surgery: overview of current practice patterns in 9 European countries. J Cataract Refract Surg. 2013;39(9):1421-1431. https://doi.org/10.1016/j.jcrs.2013.06.014.
  34. Lanzetta P, Loewenstein A, Vision Academy Steering C. Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. Graefes Arch Clin Exp Ophthalmol. 2017;255(7):1259-1273. https://doi.org/10.1007/s00417-017-3647-4.
  35. Tufan HA, Vural A, Gencer B, et al. Bacterial contamination of needles used for intravitreal injections: comparison between 27-gauge and 30-gauge needles. Ocul Immunol Inflamm. 2013;21(5):366-370. https://doi.org/10.3109/09273948.2013.801988.
  36. Ozkaya A, Alkin Z, Celik U, et al. Comparing the effects of three different intravitreal injection techniques on vitreous reflux and intraocular pressure. J Ocul Pharmacol Ther. 2013;29(3):325-329. https://doi.org/10.1089/jop.2012.0144.
  37. Патент РФ на изобретение № 2581219/ 11.03.2016. Бюл. № 11. Бобыкин Е.В. Способ интравитреального введения лекарственных средств в офтальмологии. [Patent RUS No 2581219/ 11.03.2016. Byul. No 11. Bobykin EV. Sposob intravitreal’nogo vvedeniya lekarstvennykh sredstv v oftal’mologii. (In Russ.)]

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Measures aimed at the prevention of infectious and inflammatory complications (n = 74)

Download (145KB)
Indexing metadata
3. Fig. 2. Topical antibiotics used for medical support of intravitreal injections (n = 74)

Download (39KB)
Indexing metadata
4. Fig. 3. The examination terms of patients after intravitreal injections (IVI) (n = 74, more than one answer is indicated in 38 questionnaires)

Download (31KB)
Indexing metadata

Copyright (c) 2019 Korotkikh S.A., Bobykin E.V., Ekgardt V.F., Malishevskaya T.N., Kubareva I.A., Akulevich T.G., Morozova O.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies